Insider Buying: AnaptysBio (NASDAQ:ANAB) Director Buys $3,840,919.20 in Stock

AnaptysBio, Inc. (NASDAQ:ANAB – Get Free Report) Director Ecor1 Capital, Llc purchased 84,120 shares of the firm’s stock in a transaction on Monday, November 16th. The stock was bought at an average price of $45.66 per share, for a total transaction of $3,840,919.20. Following the completion of the transaction, the director directly owned 7,964,214 shares in the company, valued at approximately $363,646,011.24. The trade was a 1.07% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Ecor1 Capital, Llc also recently made the following trade(s):

  • On Wednesday, November 18th, Ecor1 Capital, Llc acquired 138,093 shares of AnaptysBio stock. The shares were bought at an average price of $46.54 per share, for a total transaction of $6,426,848.22.
  • On Tuesday, November 17th, Ecor1 Capital, Llc acquired 152,367 shares of AnaptysBio stock. The shares were bought at an average cost of $45.66 per share, with a total value of $6,957,077.22.

AnaptysBio Stock Performance

Shares of NASDAQ ANAB traded up $1.45 during mid-day trading on Wednesday, hitting $47.06. The company had a trading volume of 566,852 shares, compared to its average volume of 658,208. The company has a debt-to-equity ratio of 0.17, a current ratio of 8.40 and a quick ratio of 8.40. The business’s 50-day simple moving average is $49.35 and its 200-day simple moving average is $56.27. AnaptysBio, Inc. has a 12 month low of $22.07 and a 12 month high of $72.36. The firm has a market cap of $1.40 billion, a P/E ratio of 9.49 and a beta of 0.70.

AnaptysBio (NASDAQ:ANAB – Get Free Report) last released its earnings results on Thursday, November 12th. The biotechnology company reported $0.11 earnings per share for the quarter, topping analysts’ consensus estimates of ($1.84) by $1.95. AnaptysBio had a negative return on equity of 17.54% and a net margin of 96.30%. The business had revenue of $30.27 million for the quarter, compared to the consensus estimate of $25.56 million. As a group, analysts predict that AnaptysBio, Inc. will post -1.30 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in ANAB. BlackRock Inc. bought a new position in AnaptysBio during the second quarter worth about $124,473,000. Affinity Asset Advisors LLC boosted its holdings in AnaptysBio by 111.4% during the first quarter. Affinity Asset Advisors LLC now owns 940,000 shares of the biotechnology company’s stock valued at $52,132,000 after purchasing an additional 495,308 shares in the last quarter. Goldman Sachs Group Inc. grew its stake in shares of AnaptysBio by 45.6% in the 3rd quarter. Goldman Sachs Group Inc. now owns 850,343 shares of the biotechnology company’s stock valued at $42,738,000 after purchasing an additional 266,273 shares during the period. Palo Alto Investors LP bought a new stake in shares of AnaptysBio in the 2nd quarter valued at approximately $40,735,508. Finally, First Light Asset Management LLC grew its stake in shares of AnaptysBio by 2.9% in the 2nd quarter. First Light Asset Management LLC now owns 582,004 shares of the biotechnology company’s stock valued at $39,285,000 after purchasing an additional 16,573 shares during the period.

Analysts Set New Price Targets

A number of analysts have commented on the company. JPMorgan Chase & Co. reduced their price objective on AnaptysBio from $70.00 to $60.00 and set an “overweight” rating for the company in a research report on Wednesday, September 30th. Scotiabank cut AnaptysBio to a “hold” rating and set a $70.00 price objective on the stock. in a research report on Tuesday, August 25th. TD Cowen cut their target price on AnaptysBio from $75.00 to $70.00 and set a “buy” rating for the company in a research note on Tuesday, August 25th. Leerink Partners reduced their target price on AnaptysBio from $90.00 to $81.00 and set an “outperform” rating for the company in a research report on Wednesday, September 23rd. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of AnaptysBio in a research report on Tuesday, September 22nd. Twelve research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $75.67.

Read Our Latest Report on AnaptysBio

About AnaptysBio

(Get Free Report)

AnaptysBio is a biotechnology company focused on developing antibody-based treatments for inflammatory and autoimmune diseases. Its research programs target immune pathways that may be involved in conditions with significant unmet medical needs. The company’s pipeline has included rosnilimab, an investigational antibody designed to activate the PD-1 pathway, and ANB032, an investigational antibody targeting BTLA. AnaptysBio has also developed imsidolimab, an antibody targeting the IL-36 receptor; global rights to that program were licensed to Vanda Pharmaceuticals.

Read More

Insider Buying and Selling by Quarter for AnaptysBio (NASDAQ:ANAB)

Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with MarketBeat.com's FREE daily email newsletter.